KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Total Debt (2016 - 2025)

Historic Total Debt for Jazz Pharmaceuticals (JAZZ) over the last 17 years, with Q3 2025 value amounting to $5.4 billion.

  • Jazz Pharmaceuticals' Total Debt fell 1228.18% to $5.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.4 billion, marking a year-over-year decrease of 1228.18%. This contributed to the annual value of $6.1 billion for FY2024, which is 692.63% up from last year.
  • According to the latest figures from Q3 2025, Jazz Pharmaceuticals' Total Debt is $5.4 billion, which was down 1228.18% from $5.4 billion recorded in Q2 2025.
  • In the past 5 years, Jazz Pharmaceuticals' Total Debt ranged from a high of $6.7 billion in Q2 2021 and a low of $2.1 billion during Q1 2021
  • Its 5-year average for Total Debt is $5.6 billion, with a median of $5.7 billion in 2023.
  • In the last 5 years, Jazz Pharmaceuticals' Total Debt surged by 22038.61% in 2021 and then crashed by 1228.18% in 2025.
  • Over the past 5 years, Jazz Pharmaceuticals' Total Debt (Quarter) stood at $6.0 billion in 2021, then dropped by 5.38% to $5.7 billion in 2022, then dropped by 0.2% to $5.7 billion in 2023, then rose by 6.93% to $6.1 billion in 2024, then fell by 12.24% to $5.4 billion in 2025.
  • Its Total Debt was $5.4 billion in Q3 2025, compared to $5.4 billion in Q2 2025 and $5.4 billion in Q1 2025.